For how we live.
In the phase 3 SYNCHRONIZE-2 trial, the glucagon/GLP-1 dual agonist beat placebo on weight over 76 weeks. The effect was solid but smaller than the class leaders manage, and the maker funded it.
Two phase 3 trials put the oral drug safiglipron ahead of placebo and non-inferior to dapagliflozin on HbA1c. Both ran only in China, were maker-funded, and showed dose-dependent gut side effects.
ZUPREME 1 tested a once-weekly amylin analogue that works differently from GLP-1 drugs, finding up to 9.4% weight loss at 28 weeks and gastrointestinal side-effects close to placebo. Zealand Pharma funded it.
In TRIUMPH-1, a triple hormone-receptor agonist produced a 25% average weight loss at the top dose over 80 weeks, and also eased knee pain and sleep apnoea. The trial was funded by Eli Lilly.
In 3,000 patients eligible for blood thinners, the device maker's trial found left atrial appendage closure noninferior to anticoagulant drugs, and superior for non-procedure-related bleeding at three years.
GAIT randomised 1,583 people and found neither supplement beat placebo overall. A later network meta-analysis found effects below the clinically important threshold, and smaller still in industry-independent trials.